Moreover, we found that systemic administration of mxABE resulted in greater and more durable rescue of dystrophin expression in heart tissue compared with skeletal muscle in mice, suggesting that this approach may be particularly effective to reduce the likelihood of poor outcomes or mortality in patients with DMD or other monogenic diseases that put them at high risk of cardiac failure. Here, DMD is linked to Duchenne muscular dystrophy.